secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001493152-26-009463
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity initiates 2K-patient longitudinal study for CyPath Lung diagnostic
------------------------------------------------------------------------------

- 2,000-patient longitudinal study to evaluate CyPath Lung for early lung cancer detection in high-risk patients with nodules 6-29mm.
- Study will include up to 20 sites, including a dozen VA medical centers and two large military hospitals.
- Earlier trial showed 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in nodules <20mm.
- Enrollment expected up to 18 months; patients followed up to 24 months or until definitive diagnosis.
- Murtha Cancer Center Research Program provides support and funding for federal facilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226009463/0001493152-26-009463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226009463/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer